About NCIMB
NCIMB is a company based in United Kingdom founded in 1982. NCIMB has raised $2.27 million across 3 funding rounds from investors including Maven Capital Partners, European Union and The Scottish National Investment Bank. NCIMB offers products and services including Culture Collection, Microbiology and Lab Services, Ecotoxicity Testing, Preservation and Storage, and Quality Control Products. NCIMB operates in a competitive market with competitors including Evelo Biosciences, PathogenDX, BioAgilytix, Advion and Tentamus, among others.
- Headquarter Scotland
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ncimb Ltd
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.27 M (USD)
in 3 rounds
-
Latest Funding Round
$2.27 M (USD), Series A
Apr 29, 2025
-
Investors
Maven Capital Partners
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NCIMB
NCIMB offers a comprehensive portfolio of products and services, including Culture Collection, Microbiology and Lab Services, Ecotoxicity Testing, Preservation and Storage, and Quality Control Products.
Manages bacterial strains for research and biotechnology.
Detects and identifies microorganisms for various applications.
Conducts microbial tests for ecotoxicity assessment.
Offers biological material storage and patent deposits.
Provides microorganisms for quality control testing.
Funding Insights of NCIMB
NCIMB has successfully raised a total of $2.27M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $2.27 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NCIMB
NCIMB has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Maven Capital Partners, European Union and The Scottish National Investment Bank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are targeted for private equity investments.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Development investments are channeled into Scottish enterprises and projects.
|
Locked | Locked | Locked |
Investor details for NCIMB
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NCIMB
Investment portfolio details for NCIMB
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NCIMB
Detailed financials for NCIMB
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ncimb Comparisons
Peer comparison for NCIMB
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NCIMB
NCIMB operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evelo Biosciences, PathogenDX, BioAgilytix, Advion and Tentamus, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for inflammatory diseases, COVID-19, and cancer are developed.
|
|
| Locked | Locked | Locked |
Provider of DNA-based pathogen testing kits
|
|
| Locked | Locked | Locked |
Large-molecule bioanalysis is provided for biologics and biosimilars development.
|
|
| Locked | Locked | Locked |
Microfluidics and mass spectrometry products are provided for clinical research.
|
|
| Locked | Locked | Locked |
Analytical and quality assurance services are provided for diverse industries.
|
|
| Locked | Locked | Locked |
Analytical services are provided for microbiology, chemistry, and bioprocesses sectors.
|
Detailed competitors of NCIMB
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ncimb
Complete news archive for NCIMB
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NCIMB
NCIMB was founded in 1982 and raised its 1st funding round 26 years after it was founded.
NCIMB is headquartered in United Kingdom. It is registered at Scotland, United Kingdom.
NCIMB is a funded company, having raised a total of $2.27M across 3 funding rounds to date.
NCIMB was founded in 1982 in Scotland as a provider of biorepository and microbial culture collection services. Microbiology, chemical analysis, and biomaterial storage are offered to clients in pharmaceuticals, personal care, oil and gas, food, agriculture, environmental sectors, and academia. Operations include microbial identification, patent deposits, freeze-drying, oilfield microbiology, toxicity testing, analytical services, and RD support, with a focus on industrial and academic needs.
NCIMB's top competitors include PathogenDX, Alderley Analytical and BioAgilytix.
NCIMB offers Culture Collection, Microbiology and Lab Services, Ecotoxicity Testing, Preservation and Storage, and Quality Control Products.
NCIMB has 4 investors. Key investors include Maven Capital Partners, European Union, The Scottish National Investment Bank, and E-Synergy.